International Stem Cell Corporation
Develops parthenogenetic stem cell (hpSC) technology for regenerative medicine, enabling immune-matched cell therapies and research products, with applications in bioprinting and tissue engineering.
- CEO / Founder
- Andrey Semechkin, PhD
- Team Size
- 32
- Stage
- Active
- Total Funding
- $8.8M
- Latest Round
- Private Placement - $6.3M - March 2016
- Key Investors
- Andrey Semechkin
Technology & Products
Key Products
Develops human parthenogenetic stem cell (hpSC) technology for regenerative medicine, targeting central nervous system, joint, and liver diseases. Also offers specialized cells and growth media for research and stem cell-based anti-aging products through its Lifeline Skin Care unit.
Technological Advantage
Patented parthenogenetic process allows creation of stem cell lines that match millions of individuals, reducing immune rejection in therapies; technology is defensible via patents and trade secrets.
Differentiation
Value Proposition
Provides immune-matched stem cells via parthenogenesis, reducing rejection risks in therapies and offering scalable cell lines for research and cosmetic applications, potentially lowering development costs and time-to-market.
How They Differentiate
Focus on parthenogenetic stem cells for immune-matching vs. competitors using traditional embryonic or adult stem cells; offers scalable cell banking and research products through subsidiaries.
Market & Competition
Target Customers
Biotechnology researchers, pharmaceutical companies, cosmetic industry, regenerative medicine clinics
Industry Verticals
Biotechnology; Pharmaceuticals; Cosmetics; Regenerative Medicine
Competitors
Thermo Fisher Scientific, STEMCELL Technologies, Merck KGaA
Growth & Milestones
Growth Metrics
Revenue increased to $9.09 million in 2024, a 17% increase compared to $7.79 million in 2023, with combined operating income from subsidiaries reaching $2.39 million in 2024, a 29% increase from $1.85 million in 2023.
Major Milestones
Development of first parthenogenetic homozygous stem cell line; Launch of UniStemCell™ bank initiative; Establishment of Lifeline Cell Technology and Lifeline Skin Care subsidiaries